京山輕機(000821.SZ):將繼續集中資源和精力在光伏領域進行設備開發
格隆匯4月28日丨有投資者在投資者互動平台向京山輕機(000821.SZ)提問,“貴公司與華中科大合作在研的ALD設備是否未來也可以切入半導體,光伏和半導體ALD設備有什麼差別”
京山輕機回覆稱,ALD設備在鈣鈦礦設備領域與半導體設備領域的側重方向和對成本、膜層性能等的要求不同。基於光伏市場擁有較大的規模以及公司戰略規劃的情況,公司將繼續集中資源和精力在光伏領域進行設備開發,更高質量的服務好客户。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.